Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

被引：11
|
作者：
Hamilton, E. P. [1 ]
Barve, M. A. [2 ]
Tolcher, A. W. [3 ]
Buscema, J. [4 ]
Papadopoulos, K. P. [5 ]
Zarwan, C. [6 ]
Anderson, C. K. [7 ]
Doroshow, D. [8 ]
Wang, D. [9 ]
Huebner, D. [10 ]
Jansen, V. M. [10 ]
Jarlenski, D. [10 ]
Mosher, R. [10 ]
Kaufman, J. [10 ]
Moore, K. N. [11 ]
Richardson, D. L. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[2] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[3] NEXT OncologyTM, San Antonio, TX USA
[4] Arizona Oncol Associates, Oncol, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut START, Clin Res, San Antonio, TX USA
[6] Lahey Hosp & Med Ctr, Oncol, Burlington, MA USA
[7] Willamette Valley Canc Inst, Oncol, Eugene, OR USA
[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Hematol Oncol, New York, NY 10029 USA
[9] Henry Ford Hosp, Hematol Oncol, Detroit, MI 48202 USA
[10] Mersana Therapeut Inc, Clin Dev, Cambridge, MA USA
[11] Univ Oklahoma, Sarah Cannon Res Inst, Stephenson Canc Ctr, Gynecol Oncol Dept, Oklahoma City, OK USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
836P
引用
收藏
页码：S627 / S628
页数：2
相关论文
共 50 条
  • [31] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [32] UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Hays, John L.
    Friedman, Claire Frances
    Lakhani, Nehal
    Anderson, Charles K.
    Buscema, Joseph
    Duska, Linda R.
    Hamilton, Erika P.
    Taylor, Sarah E.
    Carrington, Cassandra
    Burger, Robert Allen
    Werner, Theresa Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
    Santin, Alessandro D.
    Vergote, Ignace
    Gonzalez-Martin, Antonio
    Moore, Kathleen
    Oaknin, Ana
    Romero, Ignacio
    Diab, Sami
    Copeland, Larry J.
    Monk, Bradley J.
    Coleman, Robert L.
    Herzog, Thomas J.
    Siegel, Jonathan
    Kasten, Linda
    Schlicker, Andreas
    Schulz, Anke
    Kochert, Karl
    Walter, Annette O.
    Childs, Barrett H.
    Elbi, Cem
    Bulat, Iurie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 562 - 570
  • [34] ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
    Hernandez, A.
    Urosev, D.
    Wong, J.
    Lawn, S.
    Wu, K.
    Fu, L.
    Stahl, K.
    Lasalle, M.
    Alonzo, D. A.
    Yang, L.
    Sagoe-Wagner, A. P.
    Degefie, L.
    Kim, C.
    Wu, A.
    Chen, C. W.
    Higgins, R.
    Petersen, M.
    Colombo, R.
    Barnscher, S. D.
    Rich, J. R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S5
  • [35] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
    Moore, Kathleen N.
    O'Malley, David M.
    Vergote, Ignace
    Martin, Lainie P.
    Gonzalez-Martin, Antonio
    Malek, Karim
    Birrer, Michael J.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 46 - 52
  • [36] Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+metastatic breast cancer (MBC): phase I and phase II trial results
    Burris, H., III
    Vukelja, S.
    Krop, I.
    Modi, S.
    Klencke, B.
    Girish, S.
    Sliwkowski, M. X.
    Dresser, M.
    Phillips, G. L.
    Rugo, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 267
  • [37] Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study
    Li, Yinjuan
    Qi, Lu
    Wang, Yu
    Zhao, Xia
    Lv, Shuzhen
    Feng, Yu
    Liu, Chen
    Li, Pu
    Xiong, Bingjun
    Guo, Yihui
    Lv, Dapeng
    Liu, Yongbo
    Mao, Ting
    Yuan, Keyu
    Cheng, Xiaoqiang
    Li, Yanping
    Wang, Xinghe
    ANTI-CANCER DRUGS, 2023, 34 (06) : 763 - 774
  • [38] Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
    Yang, Huijuan
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Lou, Hanmei
    Li, Guiling
    Bu, Hualei
    Li, Rong
    Wang, Shanbing
    Shen, Shujing
    Zhang, Mingjun
    Wang, Peipei
    Feng, Zhe
    Chu, Nan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S22 - S23
  • [39] Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study
    Yu, Xianjun
    Zhang, Jian
    Tazbirkova, Andrea
    Yang, Jianwei
    Yue, Jinbo
    Sun, Yuping
    Pan, Yueyin
    Sun, Meili
    Qin, Yanru
    Shen, Lin
    Song, Rongfeng
    Ruan, Jian
    Zhou, Aiping
    Mou, Yiping
    Liu, Zimin
    Liu, Zhenyang
    Zhang, Yongchang
    Morris, Michelle
    Aghmesheh, Morteza
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
    Banerjee, Susana N.
    Oza, Amit M.
    Birrer, Michael J.
    Hamilton, Erika Paige
    Hasan, Jurjees
    Leary, Alexandra
    Moore, Kathleen N.
    Mackowiak-Matejczyk, Beata
    Pikiel, Joanna
    Ray-Coquard, Isabelle
    Trask, Peter
    Lin, Kedan
    Vaze, Anjali
    Choi, YounJeong
    Marsters, Jim
    Maslyar, Daniel J.
    Lemahieu, Vanessa
    Wang, Yulei
    Humke, Eric William
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345